P7C3 is a laboratory research chemical, not a medicine or supplement, studied for protecting brain cells and slowing age-related decline. It has protected nerve cells, muscle and bone in many animal studies, including a small monkey study, but has never been tested in a person, and no dose is established. How it works is disputed, and its proposed target enzyme is more active in several cancers. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Alanine aminotransferase (ALT) | 7–56 U/L (standard reference range) | Safety check: liver injury |
| Estimated glomerular filtration rate (eGFR) | ≥90 mL/min/1.73 m² (standard reference range) | Safety check: kidney clearance and toxicity |
| Complete blood count with differential | Standard laboratory reference ranges by age and sex | Safety check: immune and bone marrow effects |
| Fasting plasma glucose | 70–99 mg/dL (standard reference range) | Expected to change: lowered in diabetic mice |
| Plasma phosphorylated tau 217 (p-tau217) | No established target; track change from the individual's own baseline | Expected to change: only biomarker linked to its effect in an animal study |
Cadence: No frequency has been established for this compound; a research setting would follow first-in-human Phase 1 cadence: baseline, then at 2 and 4 weeks, then every 4–12 weeks while exposure continues